Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
Editor Note: For more information about this release, please scroll to bottom
LONDON, July 18, 2014 /PRNewswire/ --
On Thursday, July 17, 2014, the NASDAQ Composite ended at 4,363.45, down 1.41%, the Dow Jones Industrial Average declined 0.94%, to finish the day at 16,976.81, and the S&P 500 closed at 1,958.12, down 1.18%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 699.26, down 1.09%, while the index has advanced 6.18% in the previous three months. Investor-Edge has initiated coverage on the following equities: Incyte Corp. Ltd (NASDAQ: INCY), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Cel-Sci Corporation (NYSE MKT: CVM), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and ImmunoGen Inc. (NASDAQ: IMGN). Free research on these five companies can be accessed at:
On Thursday, shares in Incyte Corp. Ltd fluctuated between $45.08 and $47.24 before ending the session 3.61% lower at $45.35. Incyte Corp. Ltd's stock reported a trading volume of 1.64 million shares, close to its three months average volume of 1.69 million shares. Although, Incyte Corp. Ltd's shares have advanced 1.82% in the previous three months, it has declined 10.87% in the last three trading session and 10.43% on YTD basis. The stock is trading below its 50-day and 200-day moving averages of $52.51 and $52.00, respectively. Moreover, shares of the company have a Relative Strength Index (RSI) of 26.56. Sign up and read the free notes on INCY at:
ACADIA Pharmaceuticals Inc.'s stock declined 4.20%, to close the day at $19.40. The stock recorded a trading volume of 1.42 million shares, much close to its three months average volume of 1.39 million shares. The stock oscillated between $19.21 and $20.37 during the session. Over the last three trading sessions and over the past three months, ACADIA Pharmaceuticals Inc.'s shares have fallen by 12.18% and 0.21%, respectively. Further, the stock has lost 22.37% since the start of this year. The stock is trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $23.20 is greater than its 50-day moving average of $21.36. Additionally, the stock has an RSI of 35.83. The complimentary notes on ACAD can be downloaded as in PDF format at:
On Thursday, shares in Cel-Sci Corp. recorded a trading volume of 0.59 million shares, higher than its three months average volume of 0.57 million shares. The stock ended the day at $1.21, which was 0.82% below its previous day's closing of $1.22, and registered an intraday range of $1.18 and $1.25. Although Cel-Sci Corp.'s shares have lost 4.72% in the previous three months, it has advanced 8.04% in the last one month and 104.44% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $1.14 and $1.07, respectively. Furthermore, shares of the company have an RSI of 55.00. Register for free on Investor-Edge and access the latest research on CVM at:
Aegerion Pharmaceuticals Inc.'s stock finished the Thursday's session 1.12% lower at $27.43. A total of 0.75 million shares were traded, which was below its three months average volume of 1.03 million shares. The stock moved between $27.18 and $27.94 during the session. Over the last three trading session and the previous one month, Aegerion Pharmaceuticals Inc.'s shares have fallen by 5.84% and 20.28%, respectively. Additionally, from the beginning of 2014, the company's stock has declined 61.34%. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $56.16 is greater than its 50-day moving average of $32.52. Aegerion Pharmaceuticals Inc.'s stock has an RSI of 28.83. The complete research on AEGR is available for free at:
On Thursday, shares in ImmunoGen Inc. fluctuated between $10.65 and $11.29 before ending the session 4.26% lower at $10.79. The stock reported a trading volume of 1.25 million shares, above its three months average volume of 0.92 million shares. ImmunoGen Inc.'s shares have lost 2.62% in the previous three trading sessions, 17.32% in the last one month and 26.45% on YTD basis. The stock is trading below its 50-day and 200-day moving averages of $11.84 and $14.39, respectively. Moreover, shares of ImmunoGen Inc. have an RSI of 42.75. Free in depth research on IMGN is available at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.